Navigation Links
Most men with low-risk prostate cancer receive aggressive treatment
Date:7/26/2010

Most men who are diagnosed with prostate cancer appear to under undergo aggressive therapy, even if they have a low prostate-specific antigen (PSA) level and low-risk disease, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

More than 90 percent of all prostate cancers are diagnosed before the disease has spread to other parts of the body, and the five-year survival rate for these patients diagnosed with localized disease is almost 100 percent, according to background information in the article. The five-year survival rate from all stages of disease increased from 69 percent in 1975 to almost 99 percent in 2003. "The tremendous improvement in survival has been attributed to early detection and treatment," the authors write. "However, there have been concerns about the potential overdiagnosis and overtreatment of localized prostate cancer. Despite these concerns, some researchers argue that the prostate-specific antigen (PSA) level is associated with a continuum of cancer risk and recommend lowering the 4-nanogram per milliliter threshold for biopsy."

To determine current risk profiles and treatment patterns of men with prostate cancer and PSA levels below this threshold, Yu-Hsuan Shao, Ph.D., of the Cancer Institute of New Jersey, New Brunswick, and colleagues used data from the Surveillance, Epidemiology and End Results system. Of 123,934 men with newly diagnosed prostate cancer from 2004 to 2006, 14 percent had PSA levels of 4 nanograms per milliliter or lower. "The patients in these cases were less likely to have high-grade cancer, and more than half were classified as having low-risk cancer," the authors write.

"Despite their lower risk of having clinically significant disease, treatment rates for men with PSA values of 4.0 nanograms per milliliter or lower were comparable to those of men presenting with PSA values between 4.0 and 20.0 nanograms per milliliter.
'/>"/>

Contact: Michele Fisher
fisherm2@umdnj.edu
732-235-9872
JAMA and Archives Journals
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. What is the role of focal therapy in low-risk prostate cancer?
2. Value of Monitoring Low-Risk Prostate Cancer Assessed
3. Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer
4. Surveillance may be suitable treatment option for patients with low-risk prostate cancer
5. Advance Toward Test for Aggressive Prostate Cancer
6. DASH FOR DAD Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
7. Jim Huber to Serve as National Spokesman for Know Your Score: Fight Prostate Campaign at Myrtle Beach Golf Holiday in August
8. Few differences in outcomes between open and laparoscopic prostate surgery
9. Two Surgical Methods Equally Successful for Prostate Cancer
10. Genetic Mutation Linked to Prostate Cancer in Blacks
11. Statins May Benefit Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... glioblastoma brain tumor cells that uses a modified poliovirus ... establish the proper dose level, researchers at Duke Cancer ... tested in an ongoing phase 1 study, capitalizes on ... receptors that work like magnets drawing the poliovirus, which ... investigational therapy, known as PVSRIPO, uses an engineered form ...
(Date:5/21/2013)... 2013 STAR (Sensory Therapies And ... with sensory challenges and the Sensory Processing Disorder ... and advocacy of Sensory Processing Disorder present Stumbling Blocks ... Improve Quality of Life, a two-hour lecture presented by ... , Learn a method that can aid in ...
(Date:5/21/2013)... As the summer season kicks off, ... camp or beginning practice for summer or fall sports. ... or sporting activities can begin. , To help parents during ... youth sports or camp physicals at just $29. ... review a child’s medical history, perform a physical exam and ...
(Date:5/21/2013)... Diehard soccer fans will definitely want to ... the game between Manchester City and Chelsea FC ... These two teams are highly decorated in the English Premiere ... to the Busch Stadium, home of the St. Louis Cardinals, ... time that a professional sporting event and non-baseball game will ...
(Date:5/21/2013)... 21 (HealthDay News) -- Urban elementary school children ... sleep problems and suffer academically, new research indicates. ... seven to nine, we found that compromised lung ... impaired academic performance," said study author Daphne ... behavior at Brown University,s Alpert Medical School in ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 3Health News:MedSpring Offers Affordable Youth Physicals for $29 2Health News:Manchester City vs. Chelsea FC Tickets: Cheap Concert Tickets has Slashed Prices on Manchester City vs. Chelsea FC Tickets at Busch Stadium in St. Louis, MO 2Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2
... Christian Davis Furman, M.D., M.S.P.H., vice chair for ... Medicine at the University of Louisville, has been selected ... Innovation Advisors Program. She is the only Kentuckian among ... of Columbia selected to participate. The ...
... New York (CCNY) whose research unites the divergent fields ... honored this month for his pioneering work in biomedical ... photonics. SPIE will present Dr. Robert Alfano, CUNY ... the first annual Britton Chance Biomedical Optics Award January ...
... FRIDAY, Jan. 6 (HealthDay News) -- If you,re 50 or ... screened for colorectal cancer, the American Society for Gastrointestinal Endoscopy ... cancers because most cases arise from precancerous growths in the ... exam and removed before they turn into cancer. Recent ...
... Fla. (Jan. 6, 2012) A malignancy-risk gene signature ... predictive and prognostic value for patients with early stage ... researchers at Moffitt Cancer Center in Tampa, Fla., who ... the Journal of the National Cancer Institute . ...
... Linagliptin (trade name: Trajenta) has been approved since August ... adults with type 2 diabetes mellitus whose elevated blood ... It is an option for patients who do not ... the drug metformin. Moreover, linagliptin can be added if ...
... Reinberg HealthDay Reporter , THURSDAY, Jan. 5 ... U.S. advisory panel,s recommendation to lower the threshold for ... once common in gasoline and house paint, can permanently ... Committee on Childhood Lead Poisoning Prevention voted to recommend ...
Cached Medicine News:Health News:UofL geriatrician selected for new federal Innovation Advisors Program 2Health News:CCNY's Robert Alfano wins first biomedical optics award 2Health News:CCNY's Robert Alfano wins first biomedical optics award 3Health News:Resolve to Take Colon Cancer Test, Experts Say 2Health News:Researchers find malignancy-risk gene signature for early-stage non-small cell lung cancer 2Health News:Added benefit of linagliptin is not proven 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 3
(Date:5/21/2013)... , May 21, 2013  IsoRay, Inc. (AMEX: ... that it has entered into an exclusive international distribution ... complete product line in Greece . ... seed brachytherapy and medical radioisotope applications for brain cancer, ... gynecologic ("gyn") cancer. IASIS Medical is ...
(Date:5/21/2013)... 2013 Hurel Corporation ("Hurel"), a world-leading provider ... platforms, today announced the appointment of James ... Board of Directors. Dr. MacDonald is the former Executive ... Institute ("SPRI"), which was the pharmaceutical development arm of ... Co. in 2009. Over a career that ...
(Date:5/21/2013)... BioElectronics Corp. (PINKSHEETS: BIEL), the maker ... that CEO, Andrew J. Whelan ... Advisory Committee, Orthopedic and Rehabilitation Panel compelling arguments ... counter sales. "It,s been 37 years ... schema," Whelan said.  "While the old classification of ...
Breaking Medicine Technology:IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3
... NEW HAVEN, Conn., Aug. 5 Rib-X ... company focused on the,discovery and development of ... announced today that company,representatives are giving three ... Research Conference on Medicinal Chemistry, August 3-8, ...
... Aug. 5 Nexgen Spine, a leading,developer of ... disc disease, announced today that it has received ... Disc in the European,Union., "We are delighted ... mark approval," said Alastair Clemow, Ph.D., President and ...
Cached Medicine Technology:Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 2Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences 3Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
... The Vitros 950 provides power ... needs of high volume testing ... up to 900 results per ... store and perform the full ...
... Monitoring Market in 1981 with the introduction ... this system uses technology known as FPIA ... concentration in a patient. Therapeutic Drugs, used ... exhibit a narrow therapeutic range requiring close ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Architect i2000SR provides high productivity. Seamless integration optimize performance....
Medicine Products: